Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent

Objectives The purpose of this study was to observe the pharmacokinetic behavior of newly synthesized biocompatible polymers based on polyhydroxyethylaspartamide (PHEA) to be used to coat an iron oxide core to make superparamagnetic iron oxide nanoparticles (SPION). Materials and methods The isotopes [14C] and [59Fe] were used to label the polymer backbone (CLS) and iron oxide core (FLS), respectively. In addition, unradiolabeled cold superparamagnetic iron oxide nanoparticles (SPION/ULS) were synthesized to characterize particle size by dynamic light scattering, morphology by transmission electron microscopy, and in vivo magnetic resonance imaging (MRI). CLS and FLS were used separately to investigate the behavior of both the synthesized polymer and [Fe] in Sprague Dawley (SD) rats, respectively. Because radioactivity of the isotopes was different by β for CLS and γ for FLS, synthesis of the samples had to be separately prepared. Results The mean particle size of the ULS was 66.1 nm, and the biodistribution of CLS concentrations in various organs, in rank order of magnitude, was liver > kidney > small intestine > other. The biodistribution of FLS concentrations was liver > spleen > lung > other. These rank orders show that synthesized SPION mainly accumulates in the liver. The differences in the distribution were caused by the SPION metabolism. Radiolabeled polymer was metabolized by the kidney and excreted mainly in the urine; [59Fe] was recycled for erythrocyte production in the spleen and excreted mainly in the feces. The MR image of the liver after intravenous injection demonstrated that [Fe] effectively accumulated in the liver and exhibited high-contrast enhancement on T2-weighted images. Conclusion This newly synthesized, polymer-coated SPION appears to be a promising candidate for use as a liver-targeted, biocompatible iron oxide MR imaging agent.

[1]  W. Crosby,et al.  Normal functions of the spleen relative to red blood cells: a review. , 1959, Blood.

[2]  S. Yuk,et al.  Biocompatible Polyhydroxyethylaspartamide-based Micelles with Gadolinium for MRI Contrast Agents , 2010, Nanoscale research letters.

[3]  W. Forth,et al.  Iron absorption and biliary excretion of transferrin in rats , 1986, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[4]  Baoan Chen,et al.  Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice , 2010, International journal of nanomedicine.

[5]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[6]  G. Pitarresi,et al.  Water-soluble copolymers of an antiviral agent: synthesis and their interaction with a biomembrane model , 1992 .

[7]  S. Meikle,et al.  The role of positron emission tomography in the discovery and development of new drugs; As studied in laboratory animals , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[8]  Christoffer Laustsen,et al.  Superparamagnetic iron oxide polyacrylic acid coated γ-Fe2O3 nanoparticles do not affect kidney function but cause acute effect on the cardiovascular function in healthy mice. , 2013, Toxicology and applied pharmacology.

[9]  C. Marx,et al.  SPIO‐enhanced 2D‐TOF MR angiography of the portal venous system: Results of an intraindividual comparison , 1997, Journal of magnetic resonance imaging : JMRI.

[10]  B. Hamm,et al.  Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging , 2004, Investigative radiology.

[11]  M. Mack,et al.  Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. , 1996, Investigative radiology.

[12]  S. Sirr,et al.  Comparison of the biodistribution of manganese-54 DTPA and gadolinium-153 DTPA in dogs. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Stefan Miltenyi,et al.  Specific MR imaging of human lymphocytes by monoclonal antibody‐guided dextran‐magnetite particles , 1992, Magnetic resonance in medicine.

[14]  Ji‐Heung Kim,et al.  Preparation and swelling behavior of biodegradable hydrogels based on α,β‐poly(N‐2‐hydroxyethyl‐DL‐aspartamide) , 2003 .

[15]  Wei Li,et al.  First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agent , 2005, Journal of magnetic resonance imaging : JMRI.

[16]  Donghua Zhu,et al.  Biocompatible nanotemplate-engineered nanoparticles containing gadolinium: stability and relaxivity of a potential MRI contrast agent. , 2006, Journal of nanoscience and nanotechnology.

[17]  P. Caliceti,et al.  Synthesis and biopharmaceutical characterisation of new poly(hydroxyethylaspartamide) copolymers as drug carriers. , 2001, Biochimica et biophysica acta.

[18]  T. Helbich,et al.  Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. , 2003, Academic radiology.

[19]  G. Cavallaro,et al.  Chemical stability and bioavailability of acyclovir coupled to α,β-poly(N-2-hydroxyethyl)-dl-aspartamide , 1995 .

[20]  W. Pegios,et al.  Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. , 1996, Radiology.

[21]  P F Renshaw,et al.  Ferromagnetic contrast agents: A new approach , 1986, Magnetic resonance in medicine.

[22]  G. Whipple,et al.  RADIOACTIVE IRON AND ITS EXCRETION IN URINE, BILE, AND FECES , 1939, The Journal of experimental medicine.

[23]  P. Reimer,et al.  Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications , 2003, European Radiology.

[24]  R Weissleder,et al.  Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. , 1988, Radiology.

[25]  M. Taupitz,et al.  Contrast‐enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide , 1994, Journal of magnetic resonance imaging : JMRI.

[26]  J. Dobson.  Magnetic nanoparticles for drug delivery , 2006 .

[27]  C. Passirani,et al.  Long-Circulating Nanopartides Bearing Heparin or Dextran Covalently Bound to Poly(Methyl Methacrylate) , 1998, Pharmaceutical Research.

[28]  Harvey R Herschman,et al.  Molecular Imaging: Looking at Problems, Seeing Solutions , 2003, Science.

[29]  Jeff W M Bulte,et al.  Iron oxide MR contrast agents for molecular and cellular imaging , 2004, NMR in biomedicine.

[30]  Jeremy N Skepper,et al.  Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. , 2007, Biomaterials.

[31]  Tsuneji Nagai,et al.  Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. , 2008, International journal of pharmaceutics.

[32]  R. Perdrisot,et al.  Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. , 1991, Magnetic resonance imaging.

[33]  S. H. Park,et al.  Absorption, Distribution, Excretion, and Pharmacokinetics of 14C-Pyronaridine Tetraphosphate in Male and Female Sprague-Dawley Rats , 2010, Journal of biomedicine & biotechnology.

[34]  G. Giammona,et al.  Macromolecular prodrug of diflunisal. II. Investigations of in vitro release and of photochemical behaviour , 1996 .

[35]  C. Robic,et al.  Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. , 2008, Chemical reviews.

[36]  Nathalie Siauve,et al.  Liver Imaging With Ferumoxides (Feridex®): Fundamentals, Controversies, and Practical Aspects , 1998, Topics in magnetic resonance imaging : TMRI.

[37]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[38]  Toshio Hayashi,et al.  Biodegradation of copoly(L‐aspartic acid/L‐glutamic acid) in vitro , 1990, Biopolymers.

[39]  C R Wirtz,et al.  Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. , 2001, AJNR. American journal of neuroradiology.

[40]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.

[41]  Philippe Robert,et al.  Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.

[42]  R Weissleder,et al.  Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. , 1988, Radiology.

[43]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[44]  Mohit Verma,et al.  Nanotechnology and Diagnostic Imaging: New Advances in Contrast Agent Technology , 2011 .

[45]  G. Giammona,et al.  Reaction of α,β‐poly(N‐hydroxyethyl)‐DL‐aspartamide with derivatives of carboxylic acids , 1987 .

[46]  A. Ray,et al.  Syntheses and characterization of random copolymers of aspartic acid with lactic acid and glycolic acid , 1981 .